Literature DB >> 7768082

Deficient C-oxidation of nicotine.

N L Benowitz1, P Jacob, D P Sachs.   

Abstract

In most people, nicotine is extensively (70% to 80%) metabolized to cotinine by C-oxidation. In a clinical trial, a 57-year-old woman was found to have the expected plasma levels of nicotine but unusually low plasma levels of cotinine both when smoking cigarettes and while receiving transdermal nicotine. To characterize her metabolism, simultaneous infusions of deuterium-labeled nicotine (d2) and cotinine (d4) were administered, with comparison to 20 other control smokers. The clearance of nicotine was unusually low (6.5 ml/min/kg versus 17.2 ml/min/kg), and the half-life of nicotine significantly longer (348 minutes versus 138 minutes) in the index case subject compared with the control subjects. The clearance of cotinine was normal. The index case subject converted only 9% of nicotine to cotinine, compared with 72% for the control subjects. As far as we know, this is the first person with deficient C-oxidation of nicotine to be characterized. Deficient C-oxidation of nicotine is associated with a long half-life of nicotine and deficient generation of cotinine, both of which could influence the risks and addictiveness of tobacco use in affected individuals.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7768082     DOI: 10.1016/0009-9236(95)90044-6

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

1.  Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.

Authors:  Ryoko Yoshida; Miki Nakajima; Yuki Watanabe; Jun-Tack Kwon; Tsuyoshi Yokoi
Journal:  Br J Clin Pharmacol       Date:  2002-11       Impact factor: 4.335

Review 2.  Precision Medicine for Tobacco Dependence: Development and Validation of the Nicotine Metabolite Ratio.

Authors:  Cheyenne E Allenby; Kelly A Boylan; Caryn Lerman; Mary Falcone
Journal:  J Neuroimmune Pharmacol       Date:  2016-02-12       Impact factor: 4.147

Review 3.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

Review 4.  Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese.

Authors:  T Yokoi; T Kamataki
Journal:  Pharm Res       Date:  1998-04       Impact factor: 4.200

5.  Nicotine Metabolism and Smoking: Ethnic Differences in the Role of P450 2A6.

Authors:  Sharon E Murphy
Journal:  Chem Res Toxicol       Date:  2016-11-22       Impact factor: 3.739

6.  Validation of self reported smoking by serum cotinine measurement in a community-based study.

Authors:  E Vartiainen; T Seppälä; P Lillsunde; P Puska
Journal:  J Epidemiol Community Health       Date:  2002-03       Impact factor: 3.710

7.  Effects upon in-vivo nicotine metabolism reveal functional variation in FMO3 associated with cigarette consumption.

Authors:  A Joseph Bloom; Sharon E Murphy; Maribel Martinez; Linda B von Weymarn; Laura J Bierut; Alison Goate
Journal:  Pharmacogenet Genomics       Date:  2013-02       Impact factor: 2.089

Review 8.  Distribution of polymorphic variants of CYP2A6 and their involvement in nicotine addiction.

Authors:  Luis A López-Flores; Gloria Pérez-Rubio; Ramcés Falfán-Valencia
Journal:  EXCLI J       Date:  2017-03-06       Impact factor: 4.068

9.  Comparative evaluation of serum cotinine levels in chronic periodontitis and chronic obstructive pulmonary disease.

Authors:  Madhurya Nagaraj Kedlaya; Amitha Ramesh; Giridhar Belur Hosmane; Rahul Bhandary; Hakkim Rajula Sajna; Biju Thomas
Journal:  J Indian Soc Periodontol       Date:  2021-08-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.